Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Allison Bratzel maintains a Neutral rating on Humacyte (NASDAQ:HUMA) and keeps the price target at $4.

March 26, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains a Neutral rating on Humacyte with a $4 price target.
The maintenance of a Neutral rating and a $4 price target by Piper Sandler suggests no significant short-term price movement is expected. The analyst's view is likely based on current market conditions and company performance, indicating stability but not enough positive momentum for an upgrade.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100